Discovery of New Heteroaryldihydropyrimidine Compounds as HBV Capsid Protein Inhibitors Based on QSAR, Molecular Docking and Molecular Dynamics Simulations**

Abstract Hepatitis B virus (HBV) infection is a major global public health problem and a serious threat to human health. The assembly of the HBV outer shell protein is an important step in the HBV life cycle. Influencing the assembly of core proteins to block viral DNA replication has become a popular target for anti‐HBV drug development. In this study, 47 heteroarylpyrimidine (HAP) compounds were investigated by QSAR, and Topomer CoMFA and HQSAR models with strong predictive ability were developed. Eight new compounds with high activity were successfully designed by searching R groups in Topomer Search. The results of molecular docking and ADMET performance prediction showed that all these compounds have good docking scores and potential medicinal values. To further understand the possible conformations and interactions of the compounds at the protein active site, we performed molecular dynamics simulations of the four compounds with high docking scores and confirmed that these complexes have stable binding conformations by free energy mapping. The free energy calculations verified the stable binding results. These results provide an important reference and theoretical basis for the design and development of effective heteroaryldihydropyrimidine analogs as potential HBV capsid inhibitors.